Ensysce Biosciences has provided a new operational update on its pivotal Phase 3 trial PF614-301, which evaluates PF614, a next-generation oxycodone prodrug, in patients with moderate to severe acute pain following abdominoplasty surgery. The company reports that the study has now enrolled 50% of the subjects targeted for the planned interim review, a meaningful operational milestone for a small clinical-stage pain company trying to move an abuse- and overdose-resistant opioid toward the market.

Biofrontera (BFRI) – Positive Phase 3 trunk/extremities data for Ameluz PDT, sharp micro-cap sell-off
Biofrontera reports that its Phase 3 study of Ameluz® PDT for actinic keratoses on the extremities, neck and trunk met the primary endpoint, strengthening the case for a 2026 sNDA – but the stock trades lower intraday, reminding investors how noisy tiny-cap price action can be.

Protara Therapeutics (TARA) — TARA-002 Phase 2 NMIBC catalyst at the end of February 2026
Protara Therapeutics is a small-cap biotech that has quietly moved from “option on survival” to a fully funded late-stage story built around a single, high-leverage asset: TARA-002. The drug is a TLR2/NOD2 agonist derived from the same cell bank as the long-used immunotherapy OK-432 (Picibanil) and is being developed both for non-muscle invasive bladder cancer (NMIBC) and for pediatric lymphatic malformations. The near-term catalyst now staring at the tape is an updated Phase 2 read-out in BCG-unresponsive NMIBC that will be presented on 27 February 2026 and that the company itself frames as aligned with the registrational pathway for this setting.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).

Gene therapy for ultra-rare immunodeficiency (LAD-I), a hard reset after last year’s CRL and the Danon shock, and a March 28, 2026 PDUFA that could flip sentiment in a name now trading near multi-year lows. This is a classic “platform vs. execution” test in gene therapy – with an additional potential upside lever in the form of a Rare Pediatric Disease Priority Review Voucher (PRV) if approval comes through.

Quick take: RenovoRx brings fresh clinical data on its TAMP™ therapy platform to SIO 2026 (February 6). The event is not a registrational readout, but it is a real-world test of how much the market still cares about this targeted intra-arterial delivery story as the company starts to generate device revenues.

Definium Therapeutics (DFTX) is not a mature commercial pharma story; it is a clinical‑stage CNS and mental health company whose equity behaves like a classic high‑beta biotech: the tape is dominated by expectations around clinical data, regulatory interactions, and the company’s ability to fund its programs through to value‑defining milestones.